4 completed, 1 active not recruiting. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 4, Active not recruiting 1 |
Follow pharmaand GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib Rucaparib - Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer | Phase 3 | Completed | pharmaand GmbH | 34 | 2021-03-22 | 2024-05-07 |
| A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy Rucaparib, Nivolumab, Placebo Oral Tablet - Epithelial Ovarian Cancer, Primary Peritoneal | Phase 3 | Active not recruiting | pharmaand GmbH | 1097 | 2018-05-14 | 2025-06-24 |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency Rucaparib, Abiraterone acetate or Enzalutamide or Docetaxel - Metastatic Castration Resistant Prostate Cancer | Phase 3 | Completed | pharmaand GmbH | 405 | 2017-06-13 | 2025-07-25 |
| ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Chemotherapy, Rucaparib - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 3 | Completed | pharmaand GmbH | 349 | 2017-03-01 | 2023-06-09 |
| Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3) Rucaparib, Placebo - Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Completed | pharmaand GmbH | 564 | 2014-04-07 | 2023-06-09 |
Fallopian Tube Neoplasms (4) · Carcinoma, Ovarian Epithelial (3) · Ovarian Neoplasms (3) · Genital Neoplasms, Male (1) · Neoplasms (1) · Pathologic Complete Response (1) · Prostatic Neoplasms (1) · Recurrence (1)
rucaparib (5) · Abiraterone Acetate (1) · CP protocol (1) · Carboplatin (1) · Cisplatin (1) · Docetaxel (1) · Drug Therapy (1) · Gemcitabine (1) · Nivolumab (1) · Paclitaxel (1) · enzalutamide (1)
Canada (5) · Israel (5) · Italy (5) · United Kingdom (5) · Spain (4) · United States (4) · Australia (3) · Belgium (3) · Germany (3) · Poland (3) · Russia (3) · Czechia (2) · Denmark (2) · France (2) · Ireland (2)
Heidi Giordano (1)
PMID 28916367, PMID 32203306, PMID 32359490, PMID 32861537, PMID 34593565, PMID 35170751, PMID 35298906, PMID 35397664, PMID 35658487, PMID 36795891, PMID 36898948, PMID 37262961, PMID 39914419, PMID 41115469
2016 (2), 2017 (1)